On the risk of delisting of ordinary shares of Alaunos Therapeutics, Inc. (TCRT)

The International Trading System Limited (hereinafter – ITS) hereby informs on the delisting risk of ordinary shares of Alaunos Therapeutics, Inc. (ISIN US98973P3091, hereinafter – Shares, QI) from The NASDAQ Stock Market LLC (hereinafter - Nasdaq).  

Information on delisting risk of ordinary shares by Nasdaq

On July 2, 2025 Alaunos Therapeutics, Inc. (hereinafter – the Company) submitted Current report Form 8-K to The United States Securities and Exchange Commission (hereinafter – SEC). According to the report, on July 2, 2025, the Company received a written notice from Nasdaq notifying the Company that it was not in compliance with the audit committee requirements as set forth in Nasdaq Listing Rule 5605(c) to have an audit committee comprised of at least three members.

Nasdaq will provide a 180-day grace period in order to regain compliance with Listing Rules 5605(c)(4) and 5605(d)(4) to appoint a new member on the Audit Committee. The Company intends to regain compliance with Nasdaq Listing Rule 5605(c) by appointing a new Board member who meets the independence requirements. For more information, please refer to the report available on the SEC website.

Information regarding possible actions to be taken by ITS Ltd.

If Nasdaq suspends trading in the Company’s ordinary shares, ITS will prohibit submission of orders and will restrict ability to conclude agreements in respect of the Company’s ordinary shares. If the Company’s ordinary shares are delisted from Nasdaq, ITS will terminate trading in the Company’s ordinary shares. However, in case the Company’s ordinary shares become listed, or admitted to trading on another Recognised Trading Venue, ITS will consider but does not guarantee continuation of trading in the Company’s ordinary shares.